Kadmon Holdings Inc. Daily Stock Analysis

Daily Stock Analysis, KDMN, Kadmon Holdings Inc, priceseries

Kadmon Holdings Inc. Daily Stock Analysis
Stock Information
Open
9.50
Close
9.50
High
9.50
Low
9.50
Previous Close
9.50
Daily Price Gain
0.00
YTD High
9.50
YTD High Date
Nov 9, 2021
YTD Low
3.45
YTD Low Date
May 11, 2021
YTD Price Change
5.40
YTD Gain
131.71%
52 Week High
9.50
52 Week High Date
Nov 9, 2021
52 Week Low
3.45
52 Week Low Date
May 11, 2021
52 Week Price Change
5.29
52 Week Gain
125.65%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
3.17
Jul 10. 2017
3.65
13 Trading Days
15.28%
Link
LONG
Sep 7. 2017
2.74
Sep 18. 2017
2.99
7 Trading Days
9.15%
Link
LONG
Jan 11. 2018
3.87
Feb 2. 2018
5.15
15 Trading Days
33.03%
Link
LONG
Mar 8. 2018
3.78
Mar 26. 2018
4.29
12 Trading Days
13.39%
Link
LONG
Aug 21. 2018
3.44
Sep 5. 2018
3.87
10 Trading Days
12.61%
Link
LONG
Feb 14. 2019
2.26
Mar 6. 2019
2.67
13 Trading Days
18.24%
Link
LONG
Jun 26. 2019
1.84
Jul 23. 2019
2.47
18 Trading Days
34.24%
Link
LONG
Oct 15. 2019
2.66
Oct 29. 2019
2.97
10 Trading Days
11.49%
Link
LONG
Mar 23. 2020
3.36
Apr 2. 2020
3.69
8 Trading Days
9.82%
Link
LONG
Apr 8. 2020
3.94
Apr 22. 2020
4.30
9 Trading Days
9.04%
Link
LONG
Aug 6. 2020
3.82
Sep 1. 2020
4.60
18 Trading Days
20.37%
Link
LONG
Nov 16. 2020
3.49
Dec 3. 2020
4.09
12 Trading Days
17.17%
Link
LONG
Jan 13. 2021
4.29
Jan 27. 2021
4.85
9 Trading Days
12.99%
Link
LONG
Aug 2. 2021
4.31
Aug 16. 2021
4.86
10 Trading Days
12.76%
Link
LONG
Aug 20. 2021
5.04
Sep 3. 2021
5.31
10 Trading Days
5.38%
Link
Company Information
Stock Symbol
KDMN
Exchange
NYSE
Company URL
http://www.kadmon.com
Company Phone
212-308-6000
CEO
Harlan W. Waksal
Headquarters
New York
Business Address
450 EAST 29TH STREET, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001557142
About

Kadmon Holdings, Inc. is a biopharmaceutical company, which discovers, develops, and commercializes small molecules and biologics. It develops product candidates in a number of indications within autoimmune and fibrotic disease, oncology, and genetic disease. It offers ribavirin tablets and capsules, phentermine and topiramate extended-release capsules, and tetrabenazine tablets. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Description

Kadmon Holdings, LLC, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics to address unmet medical needs. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; co-promotes a product for chronic weight management; distributes products for chorea, cytomegalovirus retinitis, and for the prevention of CMV disease. It is also developing product candidates in autoimmune and fibrotic diseases, oncology, and genetic diseases. The company is headquartered in New York, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading